These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8540718)

  • 1. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages.
    Mor N; Simon B; Mezo N; Heifets L
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2073-7. PubMed ID: 8540718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.
    Mor N; Simon B; Heifets L
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1482-5. PubMed ID: 8726023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.
    Dhillon J; Mitchison DA
    Am Rev Respir Dis; 1992 Jan; 145(1):212-4. PubMed ID: 1309967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosis].
    Duanmu HJ; Liu YH; Jiang GL; Wang SM; Fu YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):192-4. PubMed ID: 15854417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
    Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
    Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
    Park SW; Tasneen R; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
    Chan CY; Au-Yeang C; Yew WW; Leung CC; Cheng AF
    Antimicrob Agents Chemother; 2004 Jan; 48(1):340-3. PubMed ID: 14693563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
    Moghazeh SL; Pan X; Arain T; Stover CK; Musser JM; Kreiswirth BN
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2655-7. PubMed ID: 8913484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
    Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages.
    Mor N; Esfandiari A
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2035-6. PubMed ID: 9303411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of rifapentine susceptibility tests for Mycobacterium tuberculosis.
    Heifets L; Sanchez T; Vanderkolk J; Pham V
    Antimicrob Agents Chemother; 1999 Jan; 43(1):25-8. PubMed ID: 9869560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.
    Dickinson JM; Mitchison DA
    Tubercle; 1987 Sep; 68(3):177-82. PubMed ID: 2834842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.
    Rifat D; Prideaux B; Savic RM; Urbanowski ME; Parsons TL; Luna B; Marzinke MA; Ordonez AA; DeMarco VP; Jain SK; Dartois V; Bishai WR; Dooley KE
    Sci Transl Med; 2018 Apr; 10(435):. PubMed ID: 29618565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.
    Rastogi N; Goh KS; Berchel M; Bryskier A
    J Antimicrob Chemother; 2000 Oct; 46(4):565-70. PubMed ID: 11020253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular growth and drug susceptibility of Mycobacterium tuberculosis in macrophages.
    Chanwong S; Maneekarn N; Makonkawkeyoon L; Makonkawkeyoon S
    Tuberculosis (Edinb); 2007 Mar; 87(2):130-3. PubMed ID: 16860611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
    Vernon A; Burman W; Benator D; Khan A; Bozeman L
    Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex.
    Bemer-Melchior P; Bryskier A; Drugeon HB
    J Antimicrob Chemother; 2000 Oct; 46(4):571-6. PubMed ID: 11020254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis.
    Dickinson JM; Mitchison DA
    Tubercle; 1987 Jun; 68(2):113-8. PubMed ID: 3116733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifapentine: its role in the treatment of tuberculosis.
    Temple ME; Nahata MC
    Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.